静脉血栓栓塞症中的血红素生成试验:一个范围审查
Maria Eduarda Machado Souza1, Letícia Gonçalves Resende Ferreira1, Nádia Regina Oliveira Silva1
1Universidade Federal de São João del-Rei, Campus Centro Oeste, Brazil.
Thrombosis research
|June 21, 2025
概括
血生成试验 (TGA) 有效预测静脉血栓栓塞 (VTE) 的风险. 像ETP和峰值这样的TGA参数升高与VTE有关,有助于抗凝剂管理.
科学领域:
- 血液学 血液学 血液学
- 临床化学 临床化学
- 血栓形成研究研究
背景情况:
- 静脉血栓塞栓症 (VTE) 构成严重的健康风险.
- 准确预测和管理VTE至关重要.
- 血栓生成试验 (TGA) 是血液静止研究中的新兴工具.
研究的目的:
- 进行对血栓生成试验 (TGA) 参数与静脉血栓塞栓症 (VTE) 之间的关系进行范围审查.
- 综合关于TGA在预测各种患者群体中VTE风险的实用性的证据.
主要方法:
- 在主要数据库 (PubMed,Embase,Cochrane等) 进行系统的文献搜索. ) 的情况.
- 包括与VTE发生相关的TGA参数的人类研究.
- 由多个研究人员进行独立选和数据提取.
主要成果:
- 包括90项研究,分析了TGA与VTE相关的各种子组 (未引起的VTE,癌症,血栓友好症等). ) 的情况.
- 在VTE患者中一直观察到TGA参数升高,特别是内源性血潜力 (ETP) 和血峰值.
- 在TGA中,TGA在一次性和复发性VTE事件中都表现出预测价值.
结论:
- 血栓生成试验 (TGA) 显示出作为VTE的诊断和预后工具的显著前景.
- 在VTE患者中,TGA可以帮助优化抗凝剂治疗的管理.
- 对TGA标准化和临床应用的进一步研究是有必要的.
相关概念视频
Venous Thrombosis III: Interprofessional Care
28
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
28
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
42
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
42
Venous Thrombosis I: Introduction
47
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
47
Venous Thrombosis IV: Nursing Management
27
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
27
Anticoagulant Drugs: Low-Molecular-Weight Heparins
924
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
924
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K


